Amy Raskin, CIO, Chevy Chase Trust Natera NTRA-Q PARTIAL SELL Feb 10, 2025

Trimmed it because it moved up 145% the past year. They have a great franchise in cancer detection recurrence. Likes it long-term.

Amy Raskin, CIO, Chevy Chase Trust

Owned

Unlock Rating

$172.190

Stock price when the opinion was issued

Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

He believes in this space, diagnostics. NTRA can make an acquiring company a nice piece of change.

BUY

A biotech that does, among other things, cancer testing which is very accurate.. She just bought it. Is growing fast and expects it to be cash-flow positive this year.

Most Recent Experts

John Hood

Croft Financial Group

Stockchase Insights

5i Research

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Sarat Sethi, Managing Partner, Douglas C. Lane & Assoc.

Douglas C. Lane & Assoc.

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.